We also found that delayed treatment with several different PDE4 inhibitors reduced the severity of fibrosis in this same model, and a recent phase 3 clinical trial with BI 1015550, a preferential inhibitor of the PDE4B subtype, reduced the rate of lung function decline in patients with IPF48. This evidence concerns the gene PDE4A and fibrosis.